Laura Légat

Laura Légat

Auto-generated profile, based on publicly available information

Laura Légat

Department of Pharmacology, Research Group Experimental Pharmacology (EFAR), Center for Neurosciences, (C4N) Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
LLLaura Légat
Laura Légat
SLSven Van Laere
Sven Van Laere
MNMarc Nyssen
Marc Nyssen
SSStephane Steurbaut
Stephane Steurbaut
ADAlain G Dupont
Alain G Dupont
PCPieter Cornu
Pieter Cornu
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Worldwide the burden of allergies, and in particular drug allergies, is growing. In the process of prescribing, dispensing or administering a drug, a medication error can occur, which can have adverse consequences, for example when a drug is given to a patient with a documented allergy to this particular drug. Computerized physician order entry systems (CPOE) with built-in clinical decision support systems (CDSS) have the potential to prevent these medication errors and consequent adverse events. Objective: In this systematic review, we provide a comprehensive overview regarding all aspects of CDSS for drug allergies including development, implementation, coding terminologies, and outcome evaluation. Methods: PRISMA guidelines were followed and searches were conducted in five databases using CPOE, CDSS, alerts, and allergic or allergy as keywords. Results: Of the 3,160 articles considered, 60 met the inclusion criteria. Nine additional articles were added based on expert opinion, resulting in a total of 69 articles. Large heterogeneity across study objectives, study designs, study populations and reported results was found. Several key findings were identified. Evidence of the usefulness of CDS for drug allergies has been documented. Nevertheless, there are some important problems associated with their use. Accurate and structured documenting of drug allergy information in the electronic health record is difficult, as it is often not clear for healthcare providers how and where to document drug allergies. Besides underreporting of drug allergies, outdated or inaccurate drug allergy information in the electronic health record poses an important problem. Research on the use of coding terminologies for documenting drug allergies is sparse. There is a lack of use of a generally accepted standard terminology for the structured documentation of allergy information. A last key finding is the consistently reported low specificity of drug allergy alerts. Current systems have high alert override rates of up to 90% leading to alert fatigue. Important challenges remain for increasing the specificity of drug allergy alerts. We only found one study specifically reporting on outcome related to CDSS for drug allergies. It showed that ADEs resulting from overridden drug allergy alerts do not occur frequently. Conclusions: Accurate and comprehensive recording of drug allergies is required for the good use of CDSS for drug allergy screening. We found considerable variation in the way drug allergies are recorded in the EHR. It remains difficult to reduce drug allergy alert overload while keeping patient safety as highest priority. Future research should focus on improving alert specificity, thereby reducing override rates and alert fatigue. Also the effect on patient outcome and the cost-effectiveness should be evaluated.

25 May 2020 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
ADAlain G. Dupont
Alain G. Dupont
LLLaura Légat
Laura Légat

3 May 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LLLaura Légat
Laura Légat
ISIlse Smolders
Ilse Smolders
ADAlain G. Dupont
Alain G. Dupont
Aim: It is well-established that angiotensin II exerts a dampening effect on the baroreflex within the nucleus tractus solitarii (NTS), the principal brainstem site for termination of baroreceptor afferents and which is densely populated with gamma-aminobutyric acid (GABA)ergic neurons and nerve terminals. The present study was designed to investigate whether local release of GABA is involved in the effects mediated by local angiotensin II within the NTS. Methods: In vivo microdialysis was used for measurement of extracellular glutamate and GABA levels and for infusion of angiotensin II within the NTS of conscious normotensive Wistar rats. The mean arterial pressure (MAP) and heart rate response to local infusion of angiotensin II were subsequently monitored with a pressure transducer under anesthesia. The angiotensin II type 1 receptor (AT1R) antagonist, candesartan, was used to assess whether responses were AT1R dependent and the nitric oxide (NO) synthase inhibitor, N(ω)-nitro-L-arginine methyl ester (L-NAME), was used to assess the involvement of NO in the evoked responses by infusion of angiotensin II. The MAP and heart rate responses were monitored with a pressure transducer. Results: Local infusion into the NTS of angiotensin II induced a significant to ninefold significantly increase in extracellular GABA levels; as well as MAP was increased by 15 mmHg. These responses were both abolished by co-infusion of either, the angiotensin II type 1 receptor antagonist, candesartan, or the NO synthase inhibitor, L-NAME, demonstrating that the effect is not only AT1R dependent but also NO dependent. The pressor response to angiotensin II was reversed by co-infusion with the GABAA receptor antagonist, bicuculline. Local blockade of NO synthase decreased both, GABA and glutamate concentrations. Conclusion: Our results suggest that the AT1R mediated hypertensive response to angiotensin II within the NTS in normotensive rats is GABA and NO dependent. Nitric oxide produced within the NTS tonically potentiates local GABA and glutamate release.

19 June 2017 in Frontiers in Neuroscience
Verified
Journal Article
Open access
LLLaura Légat
Laura Légat
SBSofie Brouwers
Sofie Brouwers
ISIlse Smolders
Ilse Smolders
ADAlain G. Dupont
Alain G. Dupont
Objectives: Angiotensin II, glutamate and gamma-aminobutyric acid (GABA) interact within the rostral ventrolateral medulla and the paraventricular nucleus modulating the central regulation of blood pressure and sympathetic tone. Our aim was to assess the effects of local angiotensin II type 2 receptor stimulation within the rostral ventrolateral medulla and the paraventricular nucleus on neurotransmitter concentrations and mean arterial pressure. Methods: In vivo microdialysis was used for measurement of extracellular glutamate and GABA levels and for local infusion of the angiotensin II type 2 receptor agonist Compound 21 in the rostral ventrolateral medulla and the paraventricular nucleus of conscious normotensive Wistar rats. The mean arterial pressure response to local Compound 21 was monitored with a pressure transducer under anaesthesia. Angiotensin II type 2 receptor selectivity was assessed using the angiotensin II type 2 receptor antagonist PD123319; the GABA-A receptor antagonist bicuculline was used to assess the involvement of GABA-A receptors. Results: Infusion of C21 (0.05µg/µl/h) in the rostral ventrolateral medulla significantly increased GABA levels and lowered blood pressure. These effects were abolished by co-infusion with PD123319. No changes in neurotransmitter levels or effects on blood pressure were seen with PD123319 infusion alone. Co-infusion of bicuculline abolished the Compound 21 evoked decrease in mean arterial pressure. Infusion of Compound 21 within the paraventricular nucleus did not change extracellular neurotransmitter levels nor mean arterial pressure. Conclusion: Selective stimulation of angiotensin II type 2 receptor within the rostral ventrolateral medulla by local Compound 21 infusion reduces blood pressure and increases local GABA levels in normotensive rats. This hypotensive response requires functional GABA-A receptors, suggesting that GABAergic neurons are involved in the sympatho-inhibitory action underlying this hypotensive response.

5 June 2019 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
LLLaura Légat
Laura Légat
ISIlse Smolders
Ilse Smolders
ADAlain G. Dupont
Alain G. Dupont
Aim: The nucleus tractus solitarii (NTS) densely expresses angiotensin II type 2 receptors (AT2R), which are mainly located on inhibitory gamma-aminobutyric acid (GABA) neurons. Central AT2R stimulation reduces blood pressure, and AT2R stimulation in the rostral ventrolateral medulla (RVLM), mediates a hypotensive response through a GABAergic mechanism. We aimed to test the hypothesis that an AT2R mediated inhibition of the GABA release within the NTS might be involved in this hypotensive response, by assessing possible alterations in blood pressure and heart rate, as well as in GABA levels in normotensive Wistar rats. Methods: In vivo microdialysis was used for measurement of extracellular GABA levels and for perfusion of the selective AT2R agonist, Compound 21, within the NTS. Our set-up allowed to determine simultaneously the excitatory glutamate dialysate levels. The mean arterial pressure and heart rate responses were monitored with a pressure transducer. Results: Local perfusion of Compound 21 into the NTS did not modify blood pressure and heart rate, nor glutamate and GABA levels compared to baseline concentrations. A putative effect was also not unmasked by concomitant angiotensin II type 1 receptor blockade with candesartan. Positive control experiments confirmed that the experimental set up had enough sensitivity to detect a reduction in GABA dialysate levels and blood pressure. Conclusion: The results did not provide evidence for a role of the AT2R within the NTS in the control of blood pressure, nor for an interaction with local GABAergic signaling in normotensive rats.

1 September 2018 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
LLLaura Légat
Laura Légat
ISIlse Smolders
Ilse Smolders
ADAlain G. Dupont
Alain G. Dupont